ClinicalTrials.gg
TerminatedNCT04233073Annexa-SUpdated Mar 22, 2023Results posted

Trial of Andexanet in Patients Receiving an Oral FXa Inhibitor Who Require Urgent Surgery

A Phase 2 interventional study of andexanet alfa in Surgery, sponsored by Alexion Pharmaceuticals, Inc.. Terminated at 56 sites in 6 countries. Open to participants aged 18 Years to 84 Years. Per ClinicalTrials.gov, last updated 2023-03-22.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 2, Interventional, and Treatment

Why this study was terminated
Limited value as a single-arm study

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 84 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 303 studies in Thrombosis with a site in United States — 43 open to participants now, 49 under way, 5 of them phase 3. Thrombosis · United States.

Enrollment
166th of 188
10 · median 67
Started
2021
with 11 others
Phase 2
38 of 303
5 open now
Registered
222nd of 303
by date

Among the 303 studies in Thrombosis with a site in United States, this one is the 166th largest by enrollment of the 188 interventional ones that give a count, is one of 12 that started in 2021, is one of 38 in phase 2, and was the 222nd registered.

Thrombosis

955 studies on the registry are indexed under Thrombosis; 171 are open to participants now.

Browse Thrombosis studies →

Open to participants now

43 of the 303 studies in Thrombosis with a site in United States are open now. Recruiting first, the newest first:

38 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 126 Thrombosis studies recruiting now, 79 (63%) set no upper age limit and 16 (13%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 84 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 303 studies in Thrombosis with a site in United States, or all of them as a file.
02

Study summary

Prospective, open-label clinical trial to evaluate the efficacy and safety of andexanet alfa patients who require urgent surgery that have been anticoagulated with the FXa (activated factor X) inhibitors.

Read the detailed description

This is a multicenter, prospective, open-label study to determine the efficacy and safety of andexanet in patients who require urgent surgery who have received 1 of the following FXa inhibitors: apixaban, rivaroxaban, edoxaban, or enoxaparin. The start of surgery must be within 15 hours following the last dose of FXa inhibitor. The primary efficacy outcome will be adjudicated by an independent Endpoint Adjudication Committee.

03

Conditions studied

  • Surgery

Browse trials for

Keywords

  • Urgent Surgery
  • Thrombosis
  • Anticoagulant
  • Surgery
  • Surgical
  • Abdominal
  • Thoracic
  • Orthopedic
  • Gynecological
  • Laparoscopic
  • Neurosurgery
  • Gastrointestinal
04

Who can participate

Ages eligible
18 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All of the following criteria must be met for the patient to be eligible:

  • Either the patient or their medical proxy (or legal designee) has given written .
  • Age ≥ 18 and \< 85 years old.
  • Requires urgent surgical intervention that must occur within 12 hours of consent, for which reversal of anti-fXa activity is judged necessary.
  • Treatment with an oral FXa inhibitor (apixaban [last dose 2.5 mg or greater], rivaroxaban [last dose 10 mg or greater], edoxaban [last dose 30 mg or greater] or enoxaparin [≥ 1 mg/kg/d]):
  • ≤ 15 hours prior to start of surgery.
  • > 15 hours prior to start of surgery or unknown time from the last dose, if documented anti fXa activity is > 100 ng/mL (> 0.5 IU/mL for enoxaparin, or over the equivalent IU/mL threshold on a low molecular weight heparin assay; see Laboratory Manual) within 2 hours prior to consent. Note: Patients enrolled in this manner should receive a high-andexanet dosing regimen.
  • Have a negative pregnancy test documented prior to enrollment (for women of ).
  • Willingness to use highly effective methods of through 30 days following study drug dose (for female and male patients who are fertile).

Exclusion criteria

Exclusion Criteria:

If a patient meets any of the following criteria, he or she is not eligible:

  • Surgery for which the risk of uncontrolled or unmanageable bleeding is low.
  • Acute life-threatening bleeding (ISTH criteria) at the time of Screening:

    1. The patient has acute-overt bleeding that is potentially life-threatening, e.g., with signs or symptoms of hemodynamic compromise, such as severe hypotension, poor skin perfusion, mental confusion, low urine output that cannot be otherwise explained.
    2. The patient has overt bleeding associated with a fall in level by ≥2g/dL, OR, a hemoglobin ≤8 g/dL if no baseline hemoglobin is available.
    3. The patient has acute bleeding in a critical area or organ, such as pericardial, intracranial, or intraspinal.
  • Any surgical procedure that involves the intraoperative use of systemic, intravascular, unfractionated heparin.
  • Primary procedure for efficacy assessment is a non-surgical interventional procedure (e.g, lumbar puncture, skin , cardiac catheterization, endoscopic retrograde cholangio-pancreatography).
  • Expected survival of \< 1 month due to comorbidity.
  • Known "Do Not Resuscitate" order or similar advanced directive.
  • The patient has a recent history (within 30 days prior to screening) of a diagnosed TE as follows: venous thromboembolism (including deep vein thrombosis, pulmonary embolism, intracardiac thrombus), myocardial infarction (including asymptomatic troponin elevations), disseminated intravascular coagulation, acute traumatic coagulopathy, cerebrovascular accident, , unstable angina pectoris hospitalization, or severe peripheral vascular disease.
  • Acute decompensated heart failure or cardiogenic shock at the time of screening.
  • The patient has sepsis or septic or severe hemorrhagic shock at the time of Screening.
  • The patient has heparin-induced thrombocytopenia (with or without thrombosis).
  • Inherited coagulopathy (e.g., anti-phospholipid antibody syndrome, protein C/S deficiency, Factor V Leiden) at time of Screening.
  • count \< 80,000/µL at the time of Screening.
  • Last dose of apixaban \< 2.5 mg, rivaroxaban \< 10 mg, edoxaban \< 30 mg, or enoxaparin 40 mg.
  • The patient is pregnant or a lactating female.
  • The patient has received any of the following drugs or blood products within 7 days of enrollment:

    • Vitamin K antagonists (e.g., warfarin).
    • Dabigatran.
    • Prothrombin complex concentrate products (e.g., Kcentra®) or recombinant factor VIIa (e.g., NovoSeven®).
    • Whole blood, plasma fractions. Note: Administration of tranexamic acid, platelets or packed red blood cells is not an exclusion criterion.
  • The patient was treated with an drug \< 30 days prior to Screening.
  • Prior treatment with andexanet.
  • Known to any component of andexanet.
  • Known allergic reaction to hamster proteins.
  • Known or suspected (i.e., presumed positive) COVID-19-related illness at the time of Screening.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Interventions

  • Andexanet is a recombinant version of human FXa

    Also known as: Andexxa®, Ondexxya®

06

What researchers measure

Primary outcomes

  1. Number of Participants Achieving Effective Hemostasis

    Effective hemostasis is defined as excellent or good as assessed by the Investigator; Ineffective hemostasis is defined as moderate or poor as assessed by the Investigator. All data were prespecified to be collected as a single Arm/Group for any participant who received at least 1 dose of the study drug, regardless of their dose level.

    Time frame: Hemostasis will be assessed from the start of surgery to the end of the procedure

Secondary outcomes

  1. Percent Change From Baseline In Anti-fXa Activity To Treatment Nadir

    Baseline is defined as the last non-missing value on or before first study drug administration. On treatment nadir is the minimum value of anti-fXa activity during the period of time from the end of the andexanet bolus to the end of the andexanet infusion. All data were prespecified to be collected as a single Arm/Group for any participant who received at least 1 dose of the study drug, regardless of their dose level.

    Time frame: Baseline, Treatment nadir (not to exceed a total of 6.5 hours of andexanet dosing)

07

Results

Posted Mar 22, 2023
Limitations and caveats
The study was terminated early due to the limited value as a single-arm study.

Participant flow

Participants who required urgent surgery and received factor Xa (fXa) inhibitors (apixaban, rivaroxaban, edoxaban, or enoxaparin) before surgery were enrolled in the study.

Participant flow — Overall Study
MilestoneAndexanet Alfa
Started10
Treated with any amount of andexanet10
Efficacy set6
Completed5
Not completed5
Withdrew: Death5

Outcome measures

PrimaryNumber of Participants Achieving Effective Hemostasis

Effective hemostasis is defined as excellent or good as assessed by the Investigator; Ineffective hemostasis is defined as moderate or poor as assessed by the Investigator. All data were prespecified to be collected as a single Arm/Group for any participant who received at least 1 dose of the study drug, regardless of their dose level.

Time frame:
Hemostasis will be assessed from the start of surgery to the end of the procedure
Reported as:
Count of participants · Participants
Number of Participants Achieving Effective Hemostasis
ParticipantsAndexanet Alfa
Number of Participants Achieving Effective Hemostasis6
SecondaryPercent Change From Baseline In Anti-fXa Activity To Treatment Nadir

Baseline is defined as the last non-missing value on or before first study drug administration. On treatment nadir is the minimum value of anti-fXa activity during the period of time from the end of the andexanet bolus to the end of the andexanet infusion. All data were prespecified to be collected as a single Arm/Group for any participant who received at least 1 dose of the study drug, regardless of their dose level.

Time frame:
Baseline, Treatment nadir (not to exceed a total of 6.5 hours of andexanet dosing)
Reported as:
Median · Percent Change
Percent Change From Baseline In Anti-fXa Activity To Treatment Nadir
Percent ChangeAndexanet Alfa
Percent Change From Baseline In Anti-fXa Activity To Treatment Nadir-96.13 (-97.4 to -89.2)

Adverse events

Collected over Day 1 up to Day 37. Non-serious events are listed at a 1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Andexanet Alfa5/10 (50%)7/10 (70%)2/10 (20%)
Most frequent serious events
Most frequent serious events
EventAndexanet Alfa
Stress cardiomyopathyCardiac disorders1/10
Periprosthetic fractureInjury, poisoning and procedural complications1/10
Postprocedural hematomaInjury, poisoning and procedural complications1/10
Ischaemic strokeNervous system disorders1/10
Acute kidney injuryRenal and urinary disorders1/10
Respiratory arrestRespiratory, thoracic and mediastinal disorders1/10
ThrombosisVascular disorders1/10
Most frequent other events
Most frequent other events
EventAndexanet Alfa
AnaemiaBlood and lymphatic system disorders1/10
Vitamin B complex deficiencyMetabolism and nutrition disorders1/10
Acute kidney injuryRenal and urinary disorders1/10
Vitamin D deficiencyMetabolism and nutrition disorders1/10

Baseline characteristics

Safety Set: Participants who were enrolled into the study and treated with any amount of andexanet alfa. All data were prespecified to be collected as a single Arm/Group for any participant who received at least 1 dose of the study drug, regardless of their dose level.

Age, Continuous
Age, Continuous(Years)Andexanet Alfa
Mean79.8 (68 to 84)
Sex: Female, Male
Sex: Female, Male(Participants)Andexanet Alfa
Female7
Male3
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Andexanet Alfa
Hispanic or Latino0
Not Hispanic or Latino6
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Andexanet Alfa
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White6
More than one race0
Unknown or Not Reported0
08

Study locations

56 sites
  • Clinical Trial Site
    Phoenix, Arizona 85006, United States
  • Clinical Trial Site
    Tucson, Arizona 85724, United States
  • Clinical Trial Site
    Long Beach, California 90806, United States
  • Clinical Trial Site
    Moreno Valley, California 92555, United States
  • Clinical Trial Site
    Washington, District of Columbia 20037, United States
  • Clinical Trial Site
    Sarasota, Florida 34239, United States
  • Clinical Trial Site
    Tampa, Florida 33606, United States
  • Clinical Trial Site
    Iowa City, Iowa 52242, United States
  • Clinical Trial Site
    Boston, Massachusetts 02111, United States
  • Clinical Trial Site
    Boston, Massachusetts 02114, United States
  • Clinical Trial Site
    Camden, New Jersey 08103, United States
  • Clinical Trial Site
    Staten Island, New York 10305, United States
  • Clinical Trial Site
    Charlotte, North Carolina 28203, United States
  • Clinical Trial Site
    Durham, North Carolina 27710, United States
  • Clinical Trial Site
    Columbus, Ohio 43210, United States
  • Clinical Trial Site
    Tulsa, Oklahoma 74104, United States
  • Clinical Trial Site
    Portland, Oregon 97239, United States
  • Clinical Trial Site
    Philadelphia, Pennsylvania 19104, United States
  • Clinical Trial Site
    Pittsburgh, Pennsylvania 15212, United States
  • Clinical Trial Site
    Pittsburgh, Pennsylvania 15213, United States
  • Clinical Trial Site
    Graz, 8036, Austria
  • Clinical Trial Site
    Innsbruck, 6020, Austria
  • Clinical Trial Site
    Klagenfurt am Wörthersee, 9020, Austria
  • Clinical Trial Site
    Wien, 1090, Austria
  • Clinical Trial Site
    Clermont-Ferrand, 63003, France
  • Clinical Trial Site
    Dijon, 21070, France
  • Clinical Trial Site
    Lille, 59037, France
  • Clinical Trial Site
    Nantes, 44093, France
  • Clinical Trial Site
    Paris, 75012, France
  • Clinical Trial Site
    Paris, 75679, France
  • Clinical Trial Site
    Aachen, 52074, Germany
  • Clinical Trial Site
    Bonn, 53127, Germany
  • Clinical Trial Site
    Dortmund, 44137, Germany
  • Clinical Trial Site
    Freiburg, 79106, Germany
  • Clinical Trial Site
    Gießen, 35392, Germany
  • Clinical Trial Site
    Heidelberg, 69120, Germany
  • Clinical Trial Site
    Konstanz, 78464, Germany
  • Clinical Trial Site
    Köln, 51109, Germany
  • Clinical Trial Site
    Mainz, 55131, Germany
  • Clinical Trial Site
    Murnau Am Staffelsee, 82418, Germany
  • Clinical Trial Site
    Würzburg, 97080, Germany
  • Clinical Trial Site
    Ashkelon, 7830604, Israel
  • Clinical Trial Site
    Haifa, 3109601, Israel
  • Clinical Trial Site
    Jerusalem, 9103102, Israel
  • Clinical Trial Site
    Jerusalem, 92100, Israel
  • Clinical Trial Site
    Petah Tikva, 4941492, Israel
  • Clinical Trial Site
    Kamakura, 247-8533, Japan
  • Clinical Trial Site
    Kasuga, 816-0864, Japan
  • Clinical Trial Site
    Kawasaki, 216-8511, Japan
  • Clinical Trial Site
    Kumamoto, 860-0008, Japan
  • Clinical Trial Site
    Kumamoto, 861-8520, Japan
  • Clinical Trial Site
    Kurume, 830-8543, Japan
  • Clinical Trial Site
    Nagoya, 466-8650, Japan
  • Clinical Trial Site
    Sakai, 593-8304, Japan
  • Clinical Trial Site
    Sendai, 980-8574, Japan
  • Clinical Trial Site
    Tokyo, 113-8602, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Alexion has a public commitment to allow requests for access to study data and will be supplying a protocol, CSR, and plain language summaries.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2021 to primary completion in Nov 2021, 4 months.

Results were first posted in Mar 2023, 1 year 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2020
First posted
Jan 18, 2020
StartActual
Jun 27, 2021
Primary completionActual
Nov 23, 2021
CompletionActual
Jan 25, 2022
Results first posted
Mar 22, 2023
Last update
Mar 22, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04233073
Responsible party
Sponsor
First posted
Jan 18, 2020
Start date
Jun 27, 2021
Primary completion
Nov 23, 2021
Completion
Jan 25, 2022
Results posted
Mar 22, 2023
Last update
Mar 22, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PRT064445

Start the discussion